Menu
Not yet recruiting NCT07733557

HPV Detection Using Self-Collected Menstrual Blood

No phase Interventional Human Papillomavirus (HPV) Infection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Endometrics Menstrual Blood Collection Kit.
Who it may be relevant to
Registry conditions: Human Papillomavirus (HPV) Infection. Basic parameters: 21 years — 49 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Concordance of HPV Detection Using Self-Collected Menstrual Blood

Overview

This study is evaluating whether human papillomavirus (HPV) can be accurately detected from self-collected menstrual blood samples. Participants who have had routine clinical HPV testing within the previous 90 days will collect a menstrual blood sample at home using a study-provided collection kit. The HPV test result from the menstrual blood sample will be compared with the participant's prior clinical HPV test result to assess agreement between the two methods. The goal is to determine whether menstrual blood collection may provide a feasible, noninvasive approach for HPV testing.

Interventions

  • Device Endometrics Menstrual Blood Collection Kit
    Investigational self-collection menstrual blood sampling kit used to collect menstrual blood specimens for HPV testing and concordance assessment with prior routine clinical HPV test results.

Primary outcome measures

  • Concordance of HPV Detection Between Menstrual Blood and Clinical HPV Testing [Time frame: At completion of HPV testing, up to 75 days]

Eligibility criteria

Inclusion criteria

  • Are 21 to 49 years old.
  • Are female, have not yet gone through menopause, and expect to have a menstrual period during the study.
  • Have a cervix (have not had a hysterectomy that removed the cervix). Had a routine high-risk HPV (human papillomavirus) test within the past 90 days and received a valid result (positive or negative).
  • Receive medical care at the participating clinic and have been identified by the study team as a possible candidate for the study.
  • Can read, understand, and communicate in English.
  • Are willing and able to follow study procedures, including using a menstrual blood collection kit and returning the sample for testing.
  • Are willing to provide informed consent before any study procedures are performed.
  • May be of any race or ethnicity.

Exclusion criteria

  • Had an HPV test in the past 90 days, but the result was unclear, invalid, or could not be interpreted.
  • Are currently pregnant.
  • Have had a hysterectomy that removed the cervix.
  • Are not currently having menstrual periods or are unable to provide a menstrual blood sample during the study period.
  • Have a medical, mental health, cognitive, social, or other condition that, in the opinion of the study doctor, could make it difficult to safely participate or complete the study procedures.
  • Are unable to understand the study requirements, use the collection kit, or return the sample for testing.
  • Do not wish to participate, withdraw consent, or are unwilling to complete the required study procedures.
  • Are taking part in another research study or have another circumstance that, in the opinion of the study team, could affect study results or participant safety.
  • Are currently incarcerated.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 1 center
  • University of Virginia — Charlottesville

Identifiers

NCT: NCT07733557 · 303596

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗